This Spanish SME is a lentiviral specialized CDMO offering personalized solutions based on the review of customer´s requirements and lentivirus vector design and cloning. The company is specialized in the manufacture of research, preclinical toxicology and GMP-grade lentiviral vectors. The company is looking to collaborate with Biotech/Pharma or biotechnology dedicated companies with a genetic therapy pipeline, with the need of developing, producing or using lentivirus vectors.
The company proposes herein a technology for the development and manufacture of Lentiviral vectors by using a new type of bioreactors in comparison with the classical static bioreactors. The company´s bioreactor innovative technology allows obtaining relevant titter results comparing to other classical manufacturing technologies. Moreover, importantly, the company is developing both Upstream (USP) and Downstream (DSP) processes for a given batch. Additionally, this innovation presents a greater scalability between different size bioreactors and allows working with several bioreactors in parallel. The experience of more than two thousand lentiviral batches manufactured by the company made possible implementing this innovations within it´s manufacturing platform. The company develops and manufactures lentiviral vectors from very early stages to the manufacture for preclinical toxicology or for advanced phases requiring GMP manufacture.
Type (e.g. company, R&D institution…), field of industry and Role of Partner Sought:
The company is looking to collaborate with Biotech/Pharma or biotechnology dedicated companies with a genetic therapy pipeline, and with the need of developing, producing or using lentivirus vectors with specific characteristics. The company offers itself to develope and produce these lentiviral vectors.
Stage of Development:
Already on the market
Comments Regarding Stage of Development:
The company has preclinic, clinic and commercial production capacity of this technology.
Comments Regarding IPR Status:
Technology secrecy is assured by confidentiality agreements with colaborating companies.